BioAxone Therapeutic Inc. Announces First Patient Treatment In Acute Spinal Cord Injury Trial 
10/19/2005 5:12:38 PM

MONTREAL, Feb. 7 /CNW Telbec/ - BioAxone Therapeutics Inc., a biopharmaceutical company, has announced the first patient administration of Cethrin(R) in the Phase I/IIa clinical trial for the treatment of acute spinal cord injury. The first patient was administered Cethrin by Dr. Nicholas Theodore, Neurosurgeon at St. Joseph's Hospital & Medical Center, Phoenix, Arizona.